Negative in Ames, in vitro chromosome aberration (human lymphocytes) and rat micronucleus assays
“AHC 2224920 was negative for genotoxic potential in a complete battery of genotoxicity GLP studies (i.e., Ames test, in vitro chromosome aberration test in cultured human lymphocytes and in vivo micronuclei assay in rats).”
✓ VerifiedFDA pharmacology/toxicology review, p. 9Source ↗
Carcinogenicity
Not conducted; waiver agreed with FDA for the Demodex blepharitis indication
“As agreed with the Sponsor during their pre-NDA interaction with the Division, carcinogenicity studies were not conducted to support the approval of Lotilaner Ophthalmic Solution, 0.25%, for the treatment of Demodex blepharitis.”
✓ VerifiedFDA pharmacology/toxicology review, p. 57Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rat EFD: marked fetal weight reduction and delayed (incomplete) ossification at 50 mg/kg/day
“There was a marked effect on mean fetal weight at 50 mg/kg/day and there was an indication of a developmental delay characterized by an increased number of fetuses with incomplete ossification of individual bones of the skeleton.”
✓ VerifiedFDA pharmacology/toxicology review, p. 10Source ↗
Safety pharmacology
CNS, respiratory and cardiovascular (hERG, dog ECG) assessments: no clinically relevant effects
“The central nervous system, respiratory and cardiovascular assessments of Lotilaner were evaluated in GLP studies in vitro (hERG assay) and in vivo in rats and dogs. No clinically relevant adverse effects were noted in any of the studies.”
✓ VerifiedFDA pharmacology/toxicology review, p. 7Source ↗
Genotox: Ames
Negative
“Lotilaner was not genotoxic in the following assays: Ames assay for bacterial gene mutation, in vitro chromosomal aberration assay in cultured human peripheral blood lymphocytes, and in vivo rat micronucleus test.”
“Lotilaner was not genotoxic in the following assays: Ames assay for bacterial gene mutation, in vitro chromosomal aberration assay in cultured human peripheral blood lymphocytes, and in vivo rat micronucleus test.”
“Lotilaner was not genotoxic in the following assays: Ames assay for bacterial gene mutation, in vitro chromosomal aberration assay in cultured human peripheral blood lymphocytes, and in vivo rat micronucleus test.”
Not conducted; weight-of-evidence waiver (short, non-chronic treatment)
“Based on the totality of Sponsor’s arguments, this reviewer judged the waiver request for carcinogenicity studies receivable since the weight of evidence indicated no cause for concerns in the animals or humans, nor significant systemic exposure for a long period of time”
✓ VerifiedFDA pharmacology/toxicology review, p. 60Source ↗
Carcinogenicity timing
No carcinogenicity studies; sponsor's rationale for not conducting them accepted
“No studies were performed. The Sponsor provided a rationale for not conducting carcinogenicity studies with Lotilaner that was found to be acceptable by this reviewer”
✓ VerifiedFDA pharmacology/toxicology review, p. 10Source ↗
hERG / QT
No significant hERG block up to 100 µM (60 µg/mL)
“Lotilaner did not induce any significant block of hERG current at concentrations up to 100 µM (60 µg/mL).”
✓ VerifiedFDA pharmacology/toxicology review, p. 23Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative